Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen and Hong Kong. In 2017, Qiming raised its first US fund, and set up Qiming’s US offices in Seattle, Boston and Palo Alto. Currently Qiming manages seven US Dollar funds and five RMB funds with US$4 billion assets under management.

Qiming strives to be the investor of choice for top entrepreneurs in China. Since our debut, we have backed over 280 young, fast-growing and innovative companies across China in the internet and consumer ("Intersumer"), healthcare, information technology and clean technology sectors. Over 50 of them are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange or achieved exit through M&A. There are also nearly 20 portfolio companies that have been recognized as unicorns in the industry. And many of our portfolio companies are today’s most influential brands in their respective sectors, including Xiaomi (HK 01810), Meituan-Dianping, TutorGroup (VIPABC), Meili Inc., Meitu (HK 01357), Bilibili (Nasdaq BILI), Tigermed (SZ 300347), Gan & Lee, Zai Lab (Nasdaq ZLAB), Hexing (SH 603556), CSD (SH 603903), Tellgen (SZ 300642), AmoyDx (SZ 300685), Berry Genomics (SZ 000710), HyperStrong, We Doctor Group, Face++, UBTech, Mobike and JingChi. Qiming consistently ranks among the top venture firms in terms of returns to its investors.

Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development. With access to our partners’ experience and global network as well as our excellent industry background, we spare no efforts in helping our entrepreneurs and their companies succeed!